Posted by Michael Wonder on 23 Nov 2021
Medicare coverage of aducanumab — implications for state budgets
20 November 2021 - CMS is considering whether and under what circumstances Medicare will pay for aducanumab for Alzheimer’s disease.
A restrictive coverage determination could save the federal government money, but it would also shift substantial costs to states.
